Clinical ResearchLipid-Lowering and DiabetesPredictors of New-Onset Diabetes in Patients Treated With Atorvastatin: Results From 3 Large Randomized Clinical Trials
Key Words
Abbreviations and Acronyms
Cited by (0)
The TNT, IDEAL, and SPARCL trials were funded by Pfizer, Inc. The SPARCL Steering Committee approved the use of SPARCL trial data for this analysis, but interpretation and conclusions contained herein do not necessarily represent the position of the committee. Dr. Waters has consulted for Anthera, Aegerion, Cortria, CSL, Genentech, Pfizer, and Roche; received honoraria from Bristol-Myers Squibb and Pfizer; participated in clinical trials sponsored by Biosante, Merck Schering-Plough, Pfizer, and Roche; and owns stock options in Anthera. Dr. Kastelein receives lecture fees from Pfizer and sits on the IDEAL Steering Committee. Dr. Colhoun receives research funding from and is on the Speakers' Bureau for Pfizer. Dr. Barter has consulted for AstraZeneca, CSL, Merck, Pfizer, Roche, and Sanofi-Aventis; received honoraria from Abbott, AstraZeneca, Merck, Pfizer, and Roche; and participated in clinical trials sponsored by AstraZeneca, Merck, Pfizer, and Roche. Drs. DeMicco, Breazna, and Wun are Pfizer employees. All other authors have reported that they have no relationships to disclose.